HKSE · 1875.HK
BioDlink International Company Limited
HK$3.26-HK$0.07 (-1.95%)
BioDlink International Company Limited’s quoted price sits in the lower half of its reported 52-week range, 44.46% below the high.
Loading market information…
HKSE · 2137.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 07:34 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Brii Biosciences Limited’s quoted price sits in the lower half of its reported 52-week range, 48.42% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Brii Biosciences Limited’s next earnings report is currently expected on Mar 19, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Brii Biosciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | Aug 23, 2023 | -HK$0.28-8.58% vs estimate | HK$43.36M |
|---|
| Q4 2022 | Mar 24, 2023 | -HK$0.21-13.02% vs estimate | HK$107.51M-77.46% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$3.26-HK$0.07 (-1.95%)
BioDlink International Company Limited’s quoted price sits in the lower half of its reported 52-week range, 44.46% below the high.
HK$1.97-HK$0.10 (-4.84%)
Zhaoke Ophthalmology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.96% below the high.
HK$6.40HK$0.00 (0.0%)
Sunho Biologics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.95% below the high.
HK$2.20-HK$0.03 (-1.35%)
JW (Cayman) Therapeutics Co. Ltd’s quoted price sits in the lower half of its reported 52-week range, 47.37% below the high.
HK$8.86-HK$0.12 (-1.28%)
Beijing Airdoc Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.63% below the high.
HK$3.80HK$0.00 (0.0%)
Wuhan YZY Biopharma Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 54.76% below the high.
HK$2.52+HK$0.01 (+0.2%)
3D Medicines Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.83% below the high.
HK$4.13HK$0.00 (0.0%)
Sirnaomics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 61.47% below the high.
